Radiotheranostics Market Report and Forecast 2025-2034
Description
The global radiotheranostics market size was valued at USD 8.51 Billion in 2024, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 13.50% during the forecast period of 2025-2034 to achieve a value of USD 30.19 Billion by 2034.
Radiotheranostics: Introduction
Radiotheranostics is a unique approach where a tiny molecule is used like a double agent. First, it acts as a spy to show where cancer cells are and how many there are (diagnosis). Then, it attaches to these cells and gives them a special kind of treatment using radiation (treatment). Its like using the same tool for finding and attacking the bad cells, all in one go. This way of doing things is like a clever strategy to help treat cancer in a more precise and personalized way.
Global Radiotheranostics Market Analysis
The rising demand for personalized cancer treatment and medications is a major trend influencing the market growth. The rise in awareness about cancer treatments and evolving therapeutics approaches are all trends contributing to the increased demand for precision medicine, hence boosting the market growth. Increased initiatives by the government to implement regulatory framework towards cancer treatments with radiotheranostics therapeutics is also a major trend influencing the global radiotheranostics market growth.
The increasing number of research and development activities in radiotheranostics are also driving the market growth, for instance the treatment for cancer was a major priority for research in a joint UK-US cancer funding review which happened in March 2024. The increasing popularity of radiopharmaceuticals is also contributing to the rising radiotheranostics market share. For example, USA and Europe have approved radiopharmaceuticals for a targeted α-therapy of non-Hodgkin lymphomas and PSAM-positive prostate carcinoma. The increasing technological developments are also increasing the demand for radiotheranostics.
The continuously advancing imaging technologies, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), are also propelling the market growth. The continuous research studies and practices on finding the potential clinical applications of radiotheranostics therapeutics in cancer therapy, neurology, and cardiology are also expected to further escalate the market expansion.
Global Radiotheranostics Market Segmentations
Radiotheranostics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Radioisotope
The rising prevalence of cancer is the major factor responsible for the market growth. The increase in geriatric population is also a major factor driving the market growth globally. With increasing age body cells gets more prone to mutation resulting in development of cancer cells. The rapid adaptation of sedentary lifestyle is also contributing to the rise in cancer cases worldwide. Along with evolving lifestyles, stress has booked a huge share in such lifestyles, further contributing to rising number of cancer cases as stress is also capable of converting healthy cells into cancer cells.
Due to all the above-mentioned factors, the demand for radiotheranostics therapeutics is on high rise. Due to the targeted diagnosis approach of radiotheranostics therapeutics, it is getting traction from people and healthcare professionals. As radiotheranostics therapeutics works on personalized medicine approaches the scope of nuclear medicine in treating wide range of chronic disorders and a surging trend for precision medicine are anticipated to further propel the global radiotheranostics market growth.
Radiotheranostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Radiotheranostics: Introduction
Radiotheranostics is a unique approach where a tiny molecule is used like a double agent. First, it acts as a spy to show where cancer cells are and how many there are (diagnosis). Then, it attaches to these cells and gives them a special kind of treatment using radiation (treatment). Its like using the same tool for finding and attacking the bad cells, all in one go. This way of doing things is like a clever strategy to help treat cancer in a more precise and personalized way.
Global Radiotheranostics Market Analysis
The rising demand for personalized cancer treatment and medications is a major trend influencing the market growth. The rise in awareness about cancer treatments and evolving therapeutics approaches are all trends contributing to the increased demand for precision medicine, hence boosting the market growth. Increased initiatives by the government to implement regulatory framework towards cancer treatments with radiotheranostics therapeutics is also a major trend influencing the global radiotheranostics market growth.
The increasing number of research and development activities in radiotheranostics are also driving the market growth, for instance the treatment for cancer was a major priority for research in a joint UK-US cancer funding review which happened in March 2024. The increasing popularity of radiopharmaceuticals is also contributing to the rising radiotheranostics market share. For example, USA and Europe have approved radiopharmaceuticals for a targeted α-therapy of non-Hodgkin lymphomas and PSAM-positive prostate carcinoma. The increasing technological developments are also increasing the demand for radiotheranostics.
The continuously advancing imaging technologies, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI), are also propelling the market growth. The continuous research studies and practices on finding the potential clinical applications of radiotheranostics therapeutics in cancer therapy, neurology, and cardiology are also expected to further escalate the market expansion.
Global Radiotheranostics Market Segmentations
Radiotheranostics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Radioisotope
- Radioisotope
- Iodine-131
- Iodine-123
- Gallium-68
- Lutetium-177
- 18F with Y-90
- Oncology
- Non-oncology
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The rising prevalence of cancer is the major factor responsible for the market growth. The increase in geriatric population is also a major factor driving the market growth globally. With increasing age body cells gets more prone to mutation resulting in development of cancer cells. The rapid adaptation of sedentary lifestyle is also contributing to the rise in cancer cases worldwide. Along with evolving lifestyles, stress has booked a huge share in such lifestyles, further contributing to rising number of cancer cases as stress is also capable of converting healthy cells into cancer cells.
Due to all the above-mentioned factors, the demand for radiotheranostics therapeutics is on high rise. Due to the targeted diagnosis approach of radiotheranostics therapeutics, it is getting traction from people and healthcare professionals. As radiotheranostics therapeutics works on personalized medicine approaches the scope of nuclear medicine in treating wide range of chronic disorders and a surging trend for precision medicine are anticipated to further propel the global radiotheranostics market growth.
Radiotheranostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Bayer AG
- Progenics Pharmaceuticals, Inc. (Lantheus)
- Telix Pharmaceuticals Limited.
- ITM Radiopharma
- Life Molecular Imaging.
- RadioMedix
- IsoTherapeutics Group, LLC
- Q BioMed Inc.
- Nordic Nanovector ASA
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Radiotheranostics Market Overview
- 3.1 Global Radiotheranostics Market Historical Value (2018-2024)
- 3.2 Global Radiotheranostics Market Forecast Value (2025-2034)
- 4 Global Radiotheranostics Market Landscape
- 4.1 Global Radiotheranostics: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Radiotheranostics: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Applications
- 5 Global Radiotheranostics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Radiotheranostics Market Segmentation
- 6.1 Global Radiotheranostics Market by Radioisotope
- 6.1.1 Market Overview
- 6.1.2 Radioisotope
- 6.1.3 Iodine-131
- 6.1.4 Iodine-123
- 6.1.5 Gallium-68
- 6.1.6 Lutetium-177
- 6.1.7 18F with Y-90
- 6.2 Global Radiotheranostics Market by Applications
- 6.2.1 Market Overview
- 6.2.2 Oncology
- 6.2.3 Non-oncology
- 6.3 Global Radiotheranostics Market by Region
- 6.3.1 Market Overview
- 6.3.2 North America
- 6.3.3 Europe
- 6.3.4 Asia Pacific
- 6.3.5 Latin America
- 6.3.6 Middle East and Africa
- 7 North America Radiotheranostics Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Radiotheranostics Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Radiotheranostics Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Radiotheranostics Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Radiotheranostics Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Novartis AG
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 Bayer AG
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Progenics Pharmaceuticals, Inc.(Lantheus)
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Telix Pharmaceuticals Limited.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 ITM Radiopharma
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Life Molecular Imaging.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 RadioMedix
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 IsoTherapeutics Group, LLC
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Q BioMed Inc.
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Nordic Nanovector ASA
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
